Literature DB >> 21426450

Clinical characterization of patients developing histologically-proven fibrosing cholestatic hepatitis C post-liver transplantation.

Sanjaya K Satapathy1, Seth Sclair, M Isabel Fiel, Juan Del Rio Martin, Thomas Schiano.   

Abstract

AIM: Fibrosing cholestatic hepatitis C (FCH) post-liver transplantation (LT) is an uncommon disorder with extremely poor outcome. Using stringent histological criteria, we sought to identify cases of FCH to better characterize its incidence, clinical features and outcomes.
METHODS: From January 1991 to December 2007, 973 LT for hepatitis C virus (HCV) were performed at our center. Using the pathology database, 51 cases with a provisional diagnosis of FCH were identified. FCH was diagnosed histologically by cholestasis accompanied by thin periportal fibrous septa, ductular reaction and mild inflammation.
RESULTS: FCH was reconfirmed in 24 recipients; seven had concurrent biliary problems. Twenty-seven cases were excluded; biopsy was unavailable in nine cases, 15 did not meet the histological criteria of FCH and three had missing clinical information. All received deceased donors at a mean age of 64.4 years (15/17 aged >50 years). Mean time from LT to FCH was 7.6 months with 16 of 17 diagnosed within 1 year of LT. At diagnosis, mean viral load was 14.4 million IU/mL, bilirubin 16.2 mg/dL, aspartate aminotransferase 262 IU/mL, alanine aminotransferase 192 IU/mL and alkaline phosphatase 299 IU/mL. All 17 patients died or required re-LT a mean of 7.8 months after the FCH diagnosis.
CONCLUSION: FCH occurs infrequently and is typified by hyperbilirubinemia, donor age of more than 50 years, extremely high HCV RNA and specific histological changes occurring within the first several months post-LT with extremely poor patient and graft survival. Histology alone is not reliable for the diagnosis of FCH, especially in the setting of recurrent HCV with concurrent biliary problems.
© 2011 The Japan Society of Hepatology.

Entities:  

Year:  2011        PMID: 21426450     DOI: 10.1111/j.1872-034X.2011.00781.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  11 in total

Review 1.  Histopathological evaluation of recurrent hepatitis C after liver transplantation: a review.

Authors:  Francesco Vasuri; Deborah Malvi; Elisa Gruppioni; Walter F Grigioni; Antonia D'Errico-Grigioni
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

2.  Immunological dysfunction during or after antiviral therapy for recurrent hepatitis C reduces graft survival.

Authors:  Pratima Sharma; Amy Hosmer; Henry Appelman; Barbara McKenna; Mohammad S Jafri; Patricia Sullivan; Robert J Fontana; Anna S Lok
Journal:  Hepatol Int       Date:  2013-10       Impact factor: 6.047

3.  Early Acute Severe HCV Recurrence After Transplantation: From Universal Mortality to Cure.

Authors:  Manav Wadhawan; Vivek Vij; Kausar Makki; Nalini Bansal; Ajay Kumar
Journal:  J Clin Exp Hepatol       Date:  2016-10-29

4.  Hepatitis C Virus and Liver Transplantation.

Authors:  Kalyan Ram Bhamidimarri; Sanjaya K Satapathy; Paul Martin
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-04

5.  Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study.

Authors:  Elizabeth C Verna; Varun Saxena; James R Burton; Jacqueline G O'Leary; Jennifer L Dodge; Richard T Stravitz; Josh Levitsky; James F Trotter; Gregory T Everson; Robert S Brown; Norah A Terrault
Journal:  Transplantation       Date:  2015-08       Impact factor: 4.939

6.  Severe Cholestatic Hepatitis C in Transplant Recipients: No Longer a Threat to Graft Survival.

Authors:  Jeanne-Marie Giard; Norah A Terrault
Journal:  Clin Gastroenterol Hepatol       Date:  2015-07-17       Impact factor: 11.382

Review 7.  Outcomes and management of viral hepatitis and human immunodeficiency virus co-infection in liver transplantation.

Authors:  Stephen E Congly; Karen E Doucette; Carla S Coffin
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

Review 8.  Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future.

Authors:  Jérôme Dumortier; Olivier Boillot; Jean-Yves Scoazec
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

Review 9.  Era of direct acting antivirals in chronic hepatitis C: Who will benefit?

Authors:  James Fung
Journal:  World J Hepatol       Date:  2015-10-28

10.  Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation.

Authors:  D Issa; B Eghtesad; N N Zein; L Yerian; M Cruise; N Alkhouri; R Adams; I A Hanouneh
Journal:  Int J Organ Transplant Med       Date:  2016-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.